Gilead’s Trodelvy Basks In TROPiCS With FDA Breast Cancer Nod
Company Lays Out Development Strategy In Q4 Earnings
Executive Summary
Gilead’s big push into oncology bore more fruit with the FDA approval of Trodelvy based on the TROPiCS-02 trial. More development catalysts lie ahead for 2023, company said in its earnings.
You may also be interested in...
Promising Early Results For AZ And Daiichi’s Dato-DXd In Breast Cancer – But How Soon Can They File?
Once again choosing their words carefully, the partners talk only of ‘plans’ to file as regulators will first have to clarify when overall survival data will be required for the new antibody-drug conjugate in breast cancer.
Gilead Builds Japan Oncology Presence With Trodelvy
Gilead aims to launch its key oncology product Trodelvy by 2024 in Japan while building a dedicated business unit for oncology in the firm’s Japanese office. The firm has expanded its exclusive rights for oncology products in APAC.
Gilead Reports 61 Clinical Programs Under Way, With Over 20 In Phase III
Excluding sales declines due to Veklury, Gilead said its year-over-year sales grew 15% in the first quarter, with HIV drug Biktarvy serving as the biggest driver.